Gait Speed in Semaglutide-Inclusive Care

A small Japanese real-world study found that usual gait speed improved during a 12-month multidisciplinary obesity program that included nutrition support, individualized exercise guidance, and semaglutide. The 22 participants who completed the program increased their mean gait speed from 0.77 to 0.91 metres per second. This before-and-after result applies to the whole program. It does not show that semaglutide caused the mobility change^[1].

That distinction follows directly from the study design. The first six months involved lifestyle intervention, and semaglutide was added for months six through twelve while that support continued. Physical function was measured at baseline and month 12, but not when semaglutide began. With no untreated comparison group or six-month gait assessment, the contributions of medication, exercise, nutrition, rehabilitation, and time cannot be separated^[1].

Who took part in the program

The single-centre retrospective study covered adults treated at a specialized diabetes and obesity centre in Japan between June 2024 and November 2025. All had obesity plus a musculoskeletal disorder affecting mobility. The conditions included knee or hip osteoarthritis, low back pain, and several foot disorders. Participants also met Japan's approved indication criteria for semaglutide in obesity^[1].

Twenty-three eligible patients entered the program. One stopped after starting semaglutide because of an adverse event, leaving 22 completers in the analysis. Their mean age was 59.8 years, 17 were women, and mean body mass index was 34.4 kg/m². Half had knee osteoarthritis, while eight had foot disorders. No participant had diabetes^[1]. The analysis therefore describes a narrow clinical group rather than adults with obesity in general.

What the multidisciplinary intervention involved

Registered dietitians provided nutritional counselling every two months, with an emphasis on behaviour and weight management. Physical therapists assessed function at baseline and month 12, gave individualized exercise guidance at those visits, and provided one dedicated counselling session during the intervention. Suggested activity could include aerobic exercise or lower-extremity strengthening, with the type and intensity adjusted for symptoms and functional limits^[1].

The exercise component was not a uniform protocol. Some participants received additional rehabilitation according to clinical need, and the researchers did not standardize or systematically quantify that exposure. Physicians managed semaglutide during the second half of the program. These overlapping elements make the report useful as a description of routine multidisciplinary care, but unsuitable for estimating a medicine-specific effect^[1].

How gait speed and other outcomes changed

The primary outcome was usual, comfortable gait speed measured with a walkway system. Mean gait speed rose by 0.14 m/s, from 0.77±0.20 m/s at baseline to 0.91±0.19 m/s at month 12 (p<0.001). Participants with lower baseline gait speed tended to improve more. The correlation between baseline speed and subsequent change was r=-0.44 (p=0.043)^[2]. This exploratory correlation came from only 22 people and should not be treated as a prediction for an individual.

Mean body weight fell from 89.2 to 81.5 kg, while mean pain score decreased from 6.3 to 3.5 on an 11-point scale. Gait-speed improvement was not significantly associated with weight loss (r=0.22, p=0.32) or pain reduction (r=-0.04, p=0.84). A non-significant correlation does not prove that weight and pain played no role. The study was small and not designed to identify a mechanism^[1].

Several secondary measures did not change significantly. Grip strength remained almost unchanged, while the weight-bearing index and one-leg standing time showed no detected improvement. Average daily step count increased by 565 steps, but the p value was 0.08. Lean body mass fell from 44.7 to 41.4 kg, although that difference was also not statistically significant (p=0.40)^[1]. These mixed results argue against reducing the program's outcome to one broad claim about physical function.

Why this was not a semaglutide effect estimate

The paper reports a change within one group of completers. It did not randomly assign treatment, include a control group, or compare semaglutide with the same program without medication. It also lacked a gait-speed measurement immediately before semaglutide was added. The authors explicitly state that the absence of a control group prevents attribution of the improvements specifically to semaglutide^[1].

Completer selection adds another limit. One of 23 participants left after an adverse event, and the final analysis included only those who completed 12 months. In a group this small, one person's exclusion can matter. Exercise adherence, broader activity patterns, and extra rehabilitation were not quantified, so the study cannot determine which program elements contributed most to the gait change^[1].

What the study adds

The clearest contribution is practical: gait speed can be measured alongside body weight in routine obesity care for people whose musculoskeletal conditions limit mobility. In this clinic, the average changed in a favourable direction over one year, while strength, balance, and step-count measures did not show the same pattern. That makes gait speed a useful outcome to investigate in larger controlled studies, not proof of a standalone drug benefit.

Future research would need a comparison group, assessments before and after each program phase, and better records of exercise and rehabilitation exposure. A larger sample could also examine safety and determine whether baseline mobility truly identifies people more likely to improve. Until then, this paper supports evaluating the multidisciplinary program as a package. It does not support changing semaglutide treatment to improve walking speed.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.